AR and ER were substantially lower in frequency on CD3+T cells and CD4+/CD8+T cells from NSCLC patients compared with those derived from the control group, and a higher expression of AR and ER on CD8+T cells than that of CD4+T cells was observed in the control and lung cancer patients (Figures 6G–J, ****P < 0.0001). This evidence concerns the gene AR and non-small cell lung carcinoma.